Key result
Tailoring anticoagulant and antiplatelet therapies improves cardiovascular outcomes and patency after peripheral arterial revascularization.
Why the study?
Effective revascularization of peripheral artery disease relies on periprocedural pharmacological regulation of the clotting cascade, requiring familiarization with medication classes and postprocedural management tailored to patient-specific factors.
This review discusses the periprocedural and postprocedural management of peripheral artery disease revascularization using anticoagulant and antiplatelet agents to improve cardiovascular outcomes.
Answers are grounded in this paper and cite their sources.
Supports individualized antithrombotic regimens after peripheral revascularization; leaves open optimal protocols pending prospective trials.
Effective revascularization of peripheral artery disease relies on periprocedural pharmacological regulation of the clotting cascade. Patient-specific factors such as cardiovascular risk factors, contraindications, and individual psychosocial factors must be considered when initiating post revascularization management. Management with anticoagulant and antiplatelet agents is discussed to guide the interventionalist on which therapy may be appropriate for their patient. While exact treatment may be institution and provider dependent, the interventionist must be familiar with the available classes of medications and how they can be prescribed in the postprocedural setting to improve cardiovascular outcomes.
No takes yet. Share an insight, caveat, or question.
Taylor et al. (2022) conducted a review in Peripheral artery disease (PAD). Anticoagulation and Antiplatelet Agents was evaluated. Anticoagulant and antiplatelet therapies require patient-specific tailoring to improve cardiovascular outcomes and patency following peripheral arterial revascularization.
Synapse has enriched 10 related papers. Consider them for comparative context: